|
Rituximab in non-Hodgkin's lymphoma pivotal trial: infections |
| Patients monitored throughout treatment and >1 year follow up |
| Despite B cell depletion, incidence of infection was not increased |
| Most infections were typical of those common in normal hosts |
| Predominantly bacterial |
| Seven episodes of grade 3 infections |
| No patients experienced grade 4 infections |
|
Data from McLaughlin and coworkers [1]. |
Mohrbacher Arthritis Research & Therapy 2005 7(Suppl 3):S19 doi:10.1186/ar1739 |